Filter by year
View News and/or Blogs
Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma

News - Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali MEd pharma, a leading China-based bioanalytical CRO. Resolian now has bioanalysis laboratory operations in the U.S., U.K., Australia, and China. The company can initiate a project on four continents and easily transfer validated methods across labs, allowing therapeutic trials to extend to virtually any destination without changing bioanalytical CROs.

01 November 2023
Resolian Opens Expanded State-of-the-Art Analytical Laboratory in Fordham

News - Resolian, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its 440m² analytical laboratory in Fordham, Cambridgeshire, UK.

30 June 2023
Alliance Pharma and Drug Development Solutions Are Now Resolian

News - Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in 2022), today announced they will be operating under the new name Resolian — fully integrating the companies into one organization. This brings together the companies’ established bioanalytical laboratories and experts in the U.S., U.K., and most recently in Australia, as Resolian continues to expand and support the growing need for small and large molecule bioanalytical and analytical services globally.

17 May 2023
Drug Development Solutions Announces Significant Expansion of Analytical Laboratory Operations in Cambridge (Fordham), UK

News - The Analytical and Materials Science (AMS) team has experienced significant growth since its inception 11 years ago and have outgrown their current lab space.  To meet this rising demand, we have started work on reimagining an empty area of our site into a new state-of-the-art AMS laboratory. This lab will be over 30% larger, providing over 440 square metres of dedicated space for analytical and materials science work. 

20 February 2023
CRO Alliance Pharma’s Executive Team Grows by Four, Supporting Bioanalytical and CMC Testing Expansions

News - Alliance Pharma (Alliance), a global leader in bioanalytical, DMPK and CMC testing services in the pharmaceutical and biopharmaceutical industry, has grown their leadership team by four, bringing onboard a new Chief Operating Officer (COO), Chief Commercial Officer (CCO), Chief Financial Officer (CFO), and Chief People Officer (CPO). These leaders will support continued global expansion, which includes Alliance’s recent acquisition of U.K.-based Drug Development Solutions (DDS) from LGC and new bioanalytical laboratory opening in Australia in November.

21 September 2022
U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into Australia

News - Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions Business (DDS), a UK-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a healthcare private equity firm and KKR & Co. Inc. (KKR) (NYSE:KKR) a leading global investment firm, will become equal shareholders in the combined company. This transaction expands bioanalytical, analytical material testing and laboratory capabilities internationally for the biopharma and pharma industry, including areas of cell and gene therapy, next-generation biologics, material sciences and protein characterization.

11 August 2022
U.S. Alliance Pharma Acquires UK-based LGC’s Drug Development Solutions Business (DDS)

News - Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions Business (DDS), a UK-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a healthcare private equity firm and KKR & Co. Inc. (KKR) (NYSE:KKR) a leading global investment firm, will become equal shareholders in the combined company. This transaction expands bioanalytical, analytical material testing and laboratory capabilities internationally for the biopharma and pharma industry, including areas of cell and gene therapy, next-generation biologics, material sciences and protein characterization.

13 July 2022
Alliance Pharma agrees to acquire LGC’s Drug Development Solutions Business Unit

News - Alliance Pharma, a US-based Bioanalytical CRO and an Ampersand portfolio company, has agreed to acquire DDS, a UK-based Bioanalytical Business Unit of LGC. KKR will become an equal shareholder in the combined business alongside Ampersand Capital Partners. Backed by Ampersand and KKR, Alliance and DDS plan to expand the company’s geographic reach, broaden its laboratory capabilities and expand its service portfolio. The transaction is subject to regulatory approvals and expected to be completed in Q2 2022.

17 May 2022
Drug Development Solutions offers regulated bioanalysis on the SCIEX TripleTOF® 6600 High-Resolution Mass Spectrometry platform

News - Drug Development Solutions is pleased to announce the extension of its regulated bioanalytical LC-MS service through the implementation of a high-resolution mass spectrometer, the SCIEX TripleTOF® 6600 LC-MS/MS System.

25 November 2020